Cardiol Therapeutics Class Stock Market Value
| CRDL Stock | USD 0.95 0.03 3.06% |
| Symbol | Cardiol |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. Projected growth potential of Cardiol fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cardiol Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Cardiol Therapeutics requires distinguishing between market price and book value, where the latter reflects Cardiol's accounting equity. The concept of intrinsic value—what Cardiol Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Cardiol Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Cardiol Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardiol Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cardiol Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cardiol Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cardiol Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cardiol Therapeutics.
| 11/03/2025 |
| 02/01/2026 |
If you would invest 0.00 in Cardiol Therapeutics on November 3, 2025 and sell it all today you would earn a total of 0.00 from holding Cardiol Therapeutics Class or generate 0.0% return on investment in Cardiol Therapeutics over 90 days. Cardiol Therapeutics is related to or competes with INC Research, Connect Biopharma, Vivani Medical, Microbot Medical, InspireMD, Assertio Therapeutics, and InflaRx NV. Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibro... More
Cardiol Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cardiol Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cardiol Therapeutics Class upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 15.13 | |||
| Value At Risk | (4.72) | |||
| Potential Upside | 5.15 |
Cardiol Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cardiol Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cardiol Therapeutics' standard deviation. In reality, there are many statistical measures that can use Cardiol Therapeutics historical prices to predict the future Cardiol Therapeutics' volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.38) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.24) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cardiol Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cardiol Therapeutics February 1, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.23) | |||
| Mean Deviation | 2.48 | |||
| Coefficient Of Variation | (1,068) | |||
| Standard Deviation | 3.43 | |||
| Variance | 11.75 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.38) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.24) | |||
| Maximum Drawdown | 15.13 | |||
| Value At Risk | (4.72) | |||
| Potential Upside | 5.15 | |||
| Skewness | 0.6343 | |||
| Kurtosis | 1.87 |
Cardiol Therapeutics Backtested Returns
Cardiol Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0521, which signifies that the company had a -0.0521 % return per unit of risk over the last 3 months. Cardiol Therapeutics Class exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Cardiol Therapeutics' Standard Deviation of 3.43, mean deviation of 2.48, and Risk Adjusted Performance of (0.06) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.36, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cardiol Therapeutics will likely underperform. At this point, Cardiol Therapeutics has a negative expected return of -0.18%. Please make sure to confirm Cardiol Therapeutics' potential upside, as well as the relationship between the daily balance of power and market facilitation index , to decide if Cardiol Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.39 |
Poor reverse predictability
Cardiol Therapeutics Class has poor reverse predictability. Overlapping area represents the amount of predictability between Cardiol Therapeutics time series from 3rd of November 2025 to 18th of December 2025 and 18th of December 2025 to 1st of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cardiol Therapeutics price movement. The serial correlation of -0.39 indicates that just about 39.0% of current Cardiol Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.39 | |
| Spearman Rank Test | 0.06 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Cardiol Therapeutics Correlation, Cardiol Therapeutics Volatility and Cardiol Therapeutics Performance module to complement your research on Cardiol Therapeutics. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Cardiol Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.